{
    "clinical_study": {
        "@rank": "151491", 
        "arm_group": [
            {
                "arm_group_label": "Adjuvant Chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Adjuvant Chemotherapy(Gemcitabine, Cisplatin):Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases"
            }
        ], 
        "brief_summary": {
            "textblock": "Effect of adjuvant chemotherapy to control tumor progression in patients after cystectomy\n      for locally advanced bladder cancer."
        }, 
        "brief_title": "Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer", 
        "completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Bladder Cancer", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Effect of adjuvant chemotherapy based on Gemcitabine and Cisplatin  to control tumor\n      progression in patients after cystectomy for locally advanced bladder cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, 18 years of age or older, estimated life expectancy \u2265 6 months.\n\n          2. Pathologically confirmed localized invasive bladder cancer following standardize\n             radical cystectomy and pelvic lymphadenectomy.\n\n          3. Transitional cell carcinoma of bladder, stage pT3N0M0.Transitional cell carcinoma may\n             be with or without squamous cell carcinoma and/or adenocarcinoma components.\n\n          4. Electrocorticography(ECOG) performance status 0-2.\n\n          5. Blood routine:Absolute neutrophil count (ANC) \u2265 1500/\u03bcL,White blood cell count \u2265\n             3000/\u03bcLPlatelets \u2265 100,000/\u03bcL,Hemoglobin \u2265 10.0 g/dL,\n\n          6. Total serum bilirubin\u2264 1.5 x upper limit of normal (ULN).Serum aspartate transaminase\n             (AST; serum glutamic oxaloacetic transaminase(SGOT)) and serum alanine transaminase\n             (ALT; serum glutamic pyruvic transaminase (SGPT)) \u2264 2.5 x upper limit of normal\n             (ULN).\n\n          7. Creatinine clearance rate,Ccr \u2265 60%\n\n          8. ECG\uff1ano arrhythmias, no myocardial infarction.\n\n               -  Signed and dated informed consent document indicating that the patient (or\n                  legally acceptable representative) has been informed of all pertinent aspects of\n                  the trial prior to enrollment.\n\n               -  Willingness and ability to comply with scheduled visits, treatment plans,\n                  laboratory tests,and other study procedures.\n\n        Exclusion Criteria:\n\n          1. Past history of systemic chemotherapy\n\n          2. Serious heart and lung dysfunction.\n\n          3. Associated with central or peripheral neuropathy greater than 2 grade.\n\n          4. Evidence of distant metastasis beyond the pelvis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074189", 
            "org_study_id": "2012XLC02-1", 
            "secondary_id": "2012XLC02"
        }, 
        "intervention": {
            "arm_group_label": "Adjuvant Chemotherapy", 
            "description": "Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)", 
            "intervention_name": "Gemcitabine, Cisplatin", 
            "intervention_type": "Drug", 
            "other_name": "GCT"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chongqing", 
                    "country": "China", 
                    "state": "Chongqing", 
                    "zip": "400030"
                }, 
                "name": "Southwest hospital,China"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer", 
        "overall_official": {
            "affiliation": "Southwest Hospital, China", 
            "last_name": "Zhiwen Chen, M.D,Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "cancer progressive free survival rate", 
            "safety_issue": "Yes", 
            "time_frame": "60 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074189"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Southwest Hospital, China", 
            "investigator_full_name": "Zhiwen Chen", 
            "investigator_title": "M.D,Ph.D", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "60 months"
        }, 
        "source": "Southwest Hospital, China", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Southwest Hospital, China", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}